| Year |
Citation |
Score |
| 2023 |
McGlynn RP, Cui M, Brems B, Holbrook O, Booth RG. Development of 2-Aminotetralin-Type Serotonin 5-HT Agonists: Molecular Determinants for Selective Binding and Signaling at 5-HT, 5-HT, 5-HT, and 5-HT Receptors. Acs Chemical Neuroscience. 15: 357-370. PMID 38150333 DOI: 10.1021/acschemneuro.3c00658 |
0.431 |
|
| 2023 |
Sathe PK, Ramdasi GR, Giammatteo K, Beauzile H, Wang S, Zhang H, Kulkarni P, Booth RG, Ferris CF. Effects of (-)-MBP, a novel 5-HT agonist and 5-HT antagonist/inverse agonist on brain activity: A phMRI study on awake mice. Pharmacology Research & Perspectives. 11: e01144. PMID 37837184 DOI: 10.1002/prp2.1144 |
0.305 |
|
| 2023 |
Fragola NR, Brems BM, Mukherjee M, Cui M, Booth RG. Conformationally Selective 2-Aminotetralin Ligands Targeting the alpha2A- and alpha2C-Adrenergic Receptors. Acs Chemical Neuroscience. PMID 37104867 DOI: 10.1021/acschemneuro.3c00148 |
0.437 |
|
| 2022 |
Saraf TS, McGlynn RP, Bhatavdekar OM, Booth RG, Canal CE. FPT, a 2-Aminotetralin, Is a Potent Serotonin 5-HT, 5-HT, and 5-HT Receptor Agonist That Modulates Cortical Electroencephalogram Activity in Adult Knockout Mice. Acs Chemical Neuroscience. 13: 3629-3640. PMID 36473166 DOI: 10.1021/acschemneuro.2c00574 |
0.324 |
|
| 2022 |
Casey AB, Cui M, Booth RG, Canal CE. "Selective" serotonin 5-HT receptor antagonists. Biochemical Pharmacology. 200: 115028. PMID 35381208 DOI: 10.1016/j.bcp.2022.115028 |
0.778 |
|
| 2021 |
Casey AB, Mukherjee M, McGlynn RP, Cui M, Kohut SJ, Booth RG. A new class of serotonin 5-HT /5-HT receptor inverse agonists: Synthesis, molecular modeling, in vitro and in vivo pharmacology of novel 2-aminotetralins. British Journal of Pharmacology. PMID 34837227 DOI: 10.1111/bph.15756 |
0.765 |
|
| 2021 |
Rdova-Sintjago TC, Villa N, Canal C, Booth R. Human Serotonin 5-HT G Protein-Coupled Receptor Homology Model from the Adrenoceptor Structure: Ligand Docking and Mutagenesis Studies. International Journal of Quantum Chemistry. 112. PMID 24244046 DOI: 10.1002/qua.23231 |
0.488 |
|
| 2020 |
Armstrong JL, Casey AB, Saraf TS, Mukherjee M, Booth RG, Canal CE. ()-5-(2'-Fluorophenyl)-,-dimethyl-1,2,3,4-tetrahydronaphthalen-2-amine, a Serotonin Receptor Modulator, Possesses Anticonvulsant, Prosocial, and Anxiolytic-like Properties in an Knockout Mouse Model of Fragile X Syndrome and Autism Spectrum Disorder. Acs Pharmacology & Translational Science. 3: 509-523. PMID 32566916 DOI: 10.1021/acsptsci.9b00101 |
0.736 |
|
| 2019 |
Perry CK, Casey AB, Felsing DE, Vemula R, Zaka M, Herrington NB, Cui M, Kellogg GE, Canal CE, Booth RG. Synthesis of novel 5-substituted-2-aminotetralin analogs: 5-HT and 5-HT G protein-coupled receptor affinity, 3D-QSAR and molecular modeling. Bioorganic & Medicinal Chemistry. 115262. PMID 31882369 DOI: 10.1016/J.Bmc.2019.115262 |
0.777 |
|
| 2019 |
Felsing DE, Canal CE, Booth RG. Ligand-directed serotonin 5-HT receptor desensitization, β-arrestin recruitment, and sensitization. European Journal of Pharmacology. PMID 30689993 DOI: 10.1016/J.Ejphar.2019.01.037 |
0.539 |
|
| 2017 |
Mongeau E, Yuan G, Minden Z, Waldron S, Booth R, Felsing D, Ondrechen MJ, Jones GB. Homology Modeling Inspired Synthesis of 5-HT2A Receptor Inhibitors: A Diazepine Analogue of the Atypical Antipsychotic JL13. Central Nervous System Agents in Medicinal Chemistry. PMID 28462720 DOI: 10.2174/1871524917666170426123607 |
0.533 |
|
| 2016 |
Liu Y, Canal CE, Cordova-Sintjago TC, Zhu W, Booth RG. Mutagenesis analysis reveals distinct amino acids of the human serotonin 5-HT2C receptor underlie the pharmacology of distinct ligands. Acs Chemical Neuroscience. PMID 27580242 DOI: 10.1021/Acschemneuro.6B00124 |
0.552 |
|
| 2015 |
Canal CE, Felsing DE, Liu Y, Zhu W, Wood JT, Perry CK, Vemula R, Booth RG. Correction to An Orally Active Phenylaminotetralin-Chemotype Serotonin 5-HT7 and 5-HT1A Receptor Partial Agonist That Corrects Motor Stereotypy in Mouse Models. Acs Chemical Neuroscience. PMID 26225542 DOI: 10.1021/Acschemneuro.5B00197 |
0.521 |
|
| 2015 |
Canal CE, Felsing DE, Liu Y, Zhu W, Wood JT, Perry CK, Vemula R, Booth RG. An Orally Active Phenylaminotetralin-Chemotype Serotonin 5-HT7 and 5-HT1A Receptor Partial Agonist That Corrects Motor Stereotypy in Mouse Models. Acs Chemical Neuroscience. PMID 26011730 DOI: 10.1021/Acschemneuro.5B00099 |
0.548 |
|
| 2015 |
Sakhuja R, Kondabolu K, Córdova-Sintjago T, Travers S, Vincek AS, Kim MS, Abboud KA, Fang L, Sun Z, Canal CE, Booth RG. Novel 4-substituted-N,N-dimethyltetrahydronaphthalen-2-amines: synthesis, affinity, and in silico docking studies at serotonin 5-HT2-type and histamine H1 G protein-coupled receptors. Bioorganic & Medicinal Chemistry. 23: 1588-600. PMID 25703249 DOI: 10.1016/J.Bmc.2015.01.060 |
0.605 |
|
| 2015 |
Kasper JM, Booth RG, Peris J. Serotonin-2C receptor agonists decrease potassium-stimulated GABA release in the nucleus accumbens. Synapse (New York, N.Y.). 69: 78-85. PMID 25382408 DOI: 10.1002/Syn.21790 |
0.487 |
|
| 2014 |
Córdova-Sintjago T, Villa N, Fang L, Booth RG. Aromatic interactions impact ligand binding and function at serotonin 5-HT2C G protein-coupled receptors: Receptor homology modeling, ligand docking, and molecular dynamics results validated by experimental studies. Molecular Physics. 112: 398-407. PMID 24729635 DOI: 10.1080/00268976.2013.833656 |
0.563 |
|
| 2014 |
Canal CE, Morgan D, Felsing D, Kondabolu K, Rowland NE, Robertson KL, Sakhuja R, Booth RG. A novel aminotetralin-type serotonin (5-HT) 2C receptor-specific agonist and 5-HT2A competitive antagonist/5-HT2B inverse agonist with preclinical efficacy for psychoses. The Journal of Pharmacology and Experimental Therapeutics. 349: 310-8. PMID 24563531 DOI: 10.1124/Jpet.113.212373 |
0.58 |
|
| 2014 |
Canal CE, Morgan D, Felsing D, Kondabolu K, Rowland NE, Robertson KL, Sakhuja R, Booth RG. Erratum: A novel aminotetralin-type serotonin (5-HT)2C receptor-specific agonist and 5-HT2A competitive antagonist/5-HT2B inverse agonist with preclinical efficacy for psychoses (Journal of Pharmacology and Experimental Therapeutics (2014) 349 (310-318) DOI:10.1124/jpet.113.212373) Journal of Pharmacology and Experimental Therapeutics. 349. DOI: 10.1124/Jpet.114.06Er14 |
0.574 |
|
| 2014 |
Córdova-Sintjago TC, Liu Y, Booth RG. Molecular interactions of agonist and inverse agonist ligands at serotonin 5-HT2CG protein-coupled receptors: computational ligand docking and molecular dynamics studies validated by experimental mutagenesis results Molecular Physics. 113: 348-358. DOI: 10.1080/00268976.2014.952695 |
0.527 |
|
| 2014 |
Morgan D, Kondabolu K, Ajufo C, Orza P, Nwokolo J, Sakhuja R, Robertson K, Felsing D, Canal C, Rowland N, Booth R. A novel 5HT2 modulator as a potential antipsychotic medication Drug and Alcohol Dependence. 140: e156. DOI: 10.1016/J.Drugalcdep.2014.02.440 |
0.391 |
|
| 2013 |
Canal CE, Cordova-Sintjago T, Liu Y, Kim MS, Morgan D, Booth RG. Molecular pharmacology and ligand docking studies reveal a single amino acid difference between mouse and human serotonin 5-HT2A receptors that impacts behavioral translation of novel 4-phenyl-2-dimethylaminotetralin ligands. The Journal of Pharmacology and Experimental Therapeutics. 347: 705-16. PMID 24080681 DOI: 10.1124/Jpet.113.208637 |
0.647 |
|
| 2013 |
Kasper J, Tikamdas R, Kim MS, Macfadyen K, Aramini R, Ladd J, Bisceglia S, Booth R, Peris J. The serotonin-2 receptor modulator, (-)-trans-PAT, decreases voluntary ethanol consumption in rats. European Journal of Pharmacology. 718: 98-104. PMID 24041931 DOI: 10.1016/J.Ejphar.2013.09.008 |
0.487 |
|
| 2013 |
Morgan D, Kondabolu K, Kuipers A, Sakhuja R, Robertson KL, Rowland NE, Booth RG. Molecular and behavioral pharmacology of two novel orally-active 5HT2 modulators: potential utility as antipsychotic medications. Neuropharmacology. 72: 274-81. PMID 23665356 DOI: 10.1016/J.Neuropharm.2013.04.051 |
0.549 |
|
| 2013 |
Canal CE, Booth RG, Morgan D. Support for 5-HT2C receptor functional selectivity in vivo utilizing structurally diverse, selective 5-HT2C receptor ligands and the 2,5-dimethoxy-4-iodoamphetamine elicited head-twitch response model. Neuropharmacology. 70: 112-21. PMID 23353901 DOI: 10.1016/J.Neuropharm.2013.01.007 |
0.598 |
|
| 2012 |
Cordova-Sintjago TC, Fang L, Bruysters M, Leurs R, Booth RG. Molecular determinants of ligand binding at the human histamine H1 receptor: Site-directed mutagenesis results analyzed with ligand docking and molecular dynamics studies at H1 homology and crystal structure models. Journal of Chemical and Pharmaceutical Research. 4: 2937-2951. PMID 25013351 |
0.412 |
|
| 2012 |
Córdova-Sintjago T, Sakhuja R, Kondabolu K, Canal CE, Booth RG. Molecular Determinants for Ligand Binding at Serotonin 5-HT2A and 5-HT2C GPCRs: Experimental Affinity Results Analyzed by Molecular Modeling and Ligand Docking Studies. International Journal of Quantum Chemistry. 112: 3807-3814. PMID 23913978 DOI: 10.1002/Qua.24237 |
0.549 |
|
| 2012 |
Córdova-Sintjago T, Villa N, Canal C, Booth R. Human serotonin 5-HT2C G protein-coupled receptor homology model from the β2 adrenoceptor structure: Ligand docking and mutagenesis studies International Journal of Quantum Chemistry. 112: 140-149. DOI: 10.1002/Qua.23231 |
0.557 |
|
| 2011 |
Canal CE, Cordova-Sintjago TC, Villa NY, Fang LJ, Booth RG. Drug discovery targeting human 5-HT(2C) receptors: residues S3.36 and Y7.43 impact ligand-binding pocket structure via hydrogen bond formation. European Journal of Pharmacology. 673: 1-12. PMID 22020288 DOI: 10.1016/J.Ejphar.2011.10.006 |
0.545 |
|
| 2011 |
Ghoneim OM, Ibrahim DA, El-Deeb IM, Lee SH, Booth RG. A novel potential therapeutic avenue for autism: design, synthesis and pharmacophore generation of SSRIs with dual action. Bioorganic & Medicinal Chemistry Letters. 21: 6714-23. PMID 21982496 DOI: 10.1016/J.Bmcl.2011.09.046 |
0.43 |
|
| 2010 |
WYRICK SD, BOOTH RG, MYERS AM, OWENS CE, KULA NS, BALDESSARINI RJ, MCPHAIL AT, MAILMAN RB. ChemInform Abstract: Synthesis and Pharmacological Evaluation of 1-Phenyl-3-amino-1,2,3,4- tetrahydronaphthalenes as Ligands for a Novel Receptor with σ- Like Neuromodulatory Activity. Cheminform. 25: no-no. DOI: 10.1002/chin.199410151 |
0.408 |
|
| 2010 |
Booth RG, Neumeyer JL, Baldessarini RJ. Therapeutic and Diagnostic Agents for Parkinson’s Disease Burger's Medicinal Chemistry and Drug Discovery. 529-568. DOI: 10.1002/0471266949.Bmc105.Pub2 |
0.37 |
|
| 2009 |
Vincek AS, Booth RG. New Approach to 4-Phenyl-β-aminotetralin from 4-(3-Halophenyl)tetralen-2-ol Phenylacetate. Tetrahedron Letters. 50: 5107-5109. PMID 20161011 DOI: 10.1016/J.Tetlet.2009.06.099 |
0.312 |
|
| 2009 |
Booth RG, Fang L, Huang Y, Wilczynski A, Sivendran S. (1R, 3S)-(-)-trans-PAT: a novel full-efficacy serotonin 5-HT2C receptor agonist with 5-HT2A and 5-HT2B receptor inverse agonist/antagonist activity. European Journal of Pharmacology. 615: 1-9. PMID 19397907 DOI: 10.1016/J.Ejphar.2009.04.035 |
0.545 |
|
| 2008 |
Rowland NE, Crump EM, Nguyen N, Robertson K, Sun Z, Booth RG. Effect of (-)-trans-PAT, a novel 5-HT2C receptor agonist, on intake of palatable food in mice. Pharmacology, Biochemistry, and Behavior. 91: 176-80. PMID 18692085 DOI: 10.1016/J.Pbb.2008.07.004 |
0.43 |
|
| 2008 |
Booth RG, Fang L, Wilczynski A, Sivendren S, Sun Z, Travers S, Bruysters M, Sansuk K, Leurs R. Molecular determinants of ligand-directed signaling for the histamine H1 receptor. Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]. 57: S43-4. PMID 18345497 DOI: 10.1007/S00011-007-0621-3 |
0.606 |
|
| 2008 |
Sansuk K, Balog CI, van der Does AM, Booth R, de Grip WJ, Deelder AM, Bakker RA, Leurs R, Hensbergen PJ. GPCR proteomics: mass spectrometric and functional analysis of histamine H1 receptor after baculovirus-driven and in vitro cell free expression. Journal of Proteome Research. 7: 621-9. PMID 18177001 DOI: 10.1021/Pr7005654 |
0.419 |
|
| 2007 |
Booth RG, Moniri NH. Novel ligands stabilize stereo-selective conformations of the histamine H1 receptor to activate catecholamine synthesis. Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]. 56: S43-4. PMID 17806174 DOI: 10.1007/S00011-006-0521-Y |
0.775 |
|
| 2006 |
Moniri NH, Booth RG. Role of PKA and PKC in histamine H1 receptor-mediated activation of catecholamine neurotransmitter synthesis. Neuroscience Letters. 407: 249-53. PMID 16978782 DOI: 10.1016/J.Neulet.2006.08.051 |
0.744 |
|
| 2006 |
Ghoneim OM, Legere JA, Golbraikh A, Tropsha A, Booth RG. Novel ligands for the human histamine H1 receptor: synthesis, pharmacology, and comparative molecular field analysis studies of 2-dimethylamino-5-(6)-phenyl-1,2,3,4-tetrahydronaphthalenes. Bioorganic & Medicinal Chemistry. 14: 6640-58. PMID 16782354 DOI: 10.1016/J.Bmc.2006.05.077 |
0.656 |
|
| 2005 |
Booth RG, Moniri NH. Ligand-directed multifunctional signaling of histamine H1 receptors. Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]. 54: S44-5. PMID 15928829 DOI: 10.1007/S00011-004-0420-Z |
0.765 |
|
| 2005 |
Heinzen EL, Booth RG, Pollack GM. Neuronal nitric oxide modulates morphine antinociceptive tolerance by enhancing constitutive activity of the mu-opioid receptor. Biochemical Pharmacology. 69: 679-88. PMID 15670586 DOI: 10.1016/J.Bcp.2004.11.004 |
0.3 |
|
| 2004 |
Moniri NH, Covington-Strachan D, Booth RG. Ligand-directed functional heterogeneity of histamine H1 receptors: novel dual-function ligands selectively activate and block H1-mediated phospholipase C and adenylyl cyclase signaling. The Journal of Pharmacology and Experimental Therapeutics. 311: 274-81. PMID 15169829 DOI: 10.1124/Jpet.104.070086 |
0.778 |
|
| 2004 |
Bakker RA, Dees G, Carrillo JJ, Booth RG, López-Gimenez JF, Milligan G, Strange PG, Leurs R. Domain swapping in the human histamine H1 receptor. The Journal of Pharmacology and Experimental Therapeutics. 311: 131-8. PMID 15159444 DOI: 10.1124/jpet.104.067041 |
0.522 |
|
| 2004 |
Moniri NH, Booth RG. Functional heterogeneity of histamine H(1) receptors. Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]. 53: S71-2. PMID 15054625 DOI: 10.1007/S00011-003-0334-1 |
0.771 |
|
| 2002 |
Booth RG, Moniri NH, Bakker RA, Choksi NY, Nix WB, Timmerman H, Leurs R. A novel phenylaminotetralin radioligand reveals a subpopulation of histamine H(1) receptors. The Journal of Pharmacology and Experimental Therapeutics. 302: 328-36. PMID 12065734 DOI: 10.1124/Jpet.302.1.328 |
0.759 |
|
| 2002 |
Mottola DM, Kilts JD, Lewis MM, Connery HS, Walker QD, Jones SR, Booth RG, Hyslop DK, Piercey M, Wightman RM, Lawler CP, Nichols DE, Mailman RB. Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase. The Journal of Pharmacology and Experimental Therapeutics. 301: 1166-78. PMID 12023552 DOI: 10.1124/jpet.301.3.1166 |
0.384 |
|
| 2000 |
Choksi NY, Nix WB, Wyrick SD, Booth RG. A novel phenylaminotetralin (PAT) recognizes histamine H1 receptors and stimulates dopamine synthesis in vivo in rat brain. Brain Research. 852: 151-60. PMID 10661506 DOI: 10.1016/S0006-8993(99)02228-3 |
0.413 |
|
| 1999 |
Bucholtz EC, Brown RL, Tropsha A, Booth RG, Wyrick SD. Synthesis, evaluation, and comparative molecular field analysis of 1- phenyl-3-amino-1,2,3,4-tetrahydronaphthalenes as ligands for histamine H1 receptors Journal of Medicinal Chemistry. 42: 3041-3054. PMID 10447948 DOI: 10.1021/jm980428x |
0.503 |
|
| 1999 |
Booth RG, Owens CE, Brown RL, Bucholtz EC, Lawler CP, Wyrick SD. Putative sigma(3) sites in mammalian brain have histamine H(1) receptor properties: evidence from ligand binding and distribution studies with the novel H(1) radioligand [(3)H]-(-)-trans-1-phenyl-3-aminotetralin. Brain Research. 837: 95-105. PMID 10433992 DOI: 10.1016/S0006-8993(99)01602-9 |
0.464 |
|
| 1995 |
Wyrick SD, Booth RG, Myers AM, Owens CE, Bucholtz EC, Hooper PC, Kula NS, Baldessarini RJ, Mailman RB. 1-Phenyl-3-amino-1,2,3,4-tetrahydronaphthalenes and related derivatives as ligands for the neuromodulatory sigma 3 receptor: further structure-activity relationships. Journal of Medicinal Chemistry. 38: 3857-64. PMID 7562917 DOI: 10.1021/jm00019a016 |
0.449 |
|
| 1994 |
Myers AM, Charifson PS, Owens CE, Kula NS, McPhail AT, Baldessarini RJ, Booth RG, Wyrick SD. Conformational analysis, pharmacophore identification, and comparative molecular field analysis of ligands for the neuromodulatory sigma 3 receptor. Journal of Medicinal Chemistry. 37: 4109-17. PMID 7990111 DOI: 10.1021/jm00050a008 |
0.428 |
|
| 1994 |
Wyrick SD, Myers AM, Booth RG, Kula NS, Baldessarini RJ, Mailman RB. Synthesis of [N-C3H3]-trans-(1R,3S)-(-)-1-phenyl-3-N,N-dimethylamino-1,2,3,4-tetr ahydronaphthalene (H2-PAT) Journal of Labelled Compounds and Radiopharmaceuticals. 34: 131-134. DOI: 10.1002/jlcr.2580340205 |
0.405 |
|
| 1993 |
Wyrick SD, Booth RG, Myers AM, Owens CE, Kula NS, Baldessarini RJ, McPhail AT, Mailman RB. Synthesis and pharmacological evaluation of 1-phenyl-3-amino-1,2,3,4-tetrahydronaphthalenes as ligands for a novel receptor with sigma-like neuromodulatory activity. Journal of Medicinal Chemistry. 36: 2542-51. PMID 8102651 DOI: 10.1021/jm00069a013 |
0.451 |
|
| Show low-probability matches. |